(Press-News.org) A study by researchers at three academic medical centers has shown that screening women with a suspected risk of hereditary breast or ovarian cancer for risk-associated genes other than BRCA1 and 2 provides information that can change clinical recommendations for patients and their family members. The report from a team led by a Massachusetts General Hospital (MGH) Cancer Center investigator is being published in the August issue of JAMA Oncology.
"The traditional approach has been to test most women with suspected hereditary risk for breast and/or ovarian cancer for BRCA1/2 alone," explains senior author Leif Ellisen, MD, PhD, program director for Breast Medical Oncology at the MGH Cancer Center. "The concern about broader testing has been that the results really wouldn't change what we told women about their risk and management - either because the risk associated with the other genes are not as high as for BRCA1/2 or because the clinical practice guidelines associated with other genes are less specific. Our study shows that, even under current practice guidelines, finding mutations in these other genes is likely to change the clinical management recommendations both for patients and for family members who also carry the associated mutations."
The study examined whether use of currently available multigene panels to test for mutations in breast or ovarian cancer risk genes other than BRCA1/2 would change recommendations for women carrying those mutations. Investigators enrolled 1,069 patients who had been referred for genetic counseling for breast or ovarian cancer risk at MGH, Stanford University School of Medicine or Beth Israel Deaconess Medical Center and who did not carry BRCA1/2 mutations. For most participants, testing utilized one of two commercially available multigene panels - one a 25-gene panel, the other a 29-gene panel - screening genes associated with increased risk for breast and/or ovarian cancer and sometimes for other tumors.
Of all the screened patients, 63 were found to carry risk-associated mutations, most of which were consistent with their personal and family cancer histories. The 3.8 percent prevalence of these mutations among 1,046 patients tested with the two multigene panels - compared with 9 percent usually reported for BRCA1/2 mutations - is similar to what has been seen in previous studies. In almost one-third of these patients (20 of 63), the identified mutations were considered high-risk - including mutations associated with Lynch syndrome, which increases risk of colorectal, ovarian and other cancers. In each case, established guidelines for patients with those mutations would call for additional screenings and possibly preventive surgery that would not have been recommended on the basis of personal/family history alone.
Among those found to carry mutations conferring a low or moderate increase in cancer risk, current guidelines would have called for enhanced screening or preventive surgery for 10 patients with breast cancer risk genes and additional screening for 3 patients with mutations associated with pancreas cancer risk. Overall, 52 percent of patients in whom a mutation was identified would be recommended for additional screening or preventive measures above and beyond what would be called for by personal and family history. In addition, the presence of the identified mutations would lead to recommendations that close female relatives of 72 percent of the patients also be screened for the mutations, which if present would change their recommended clinical management as well.
"These results suggest that multi-gene testing can provide important additional information to guide recommendations for screening and prevention of future cancers," Ellisen explains. "For example, results that point to a higher risk of breast cancer than would be predicted by history alone might call for breast MRI in addition to mammograms. The Lynch syndrome mutations signify a need for increased colorectal cancer screening and in some cases preventive hysterectomy or ovariectomy. But it's important to note that multigene genetic testing is not appropriate for everyone and is most useful where personal and family histories suggest hereditary cancer, which is not the case for most patients with breast or ovarian cancer."
A professor of Medicine at Harvard Medical School, Ellisen adds that the next step will be to examine whether recommendations based on multigene testing lead to better prevention, early detection and improved patient survival, a project that will take many years. "These future studies will help us refine and modify gene-based management recommendations over time. We've been testing for BRCA1/2 for more than 15 years, and outcome studies and guideline modifications are still ongoing. Genetic testing and its interpretation are getting more complex, so now more than ever, it makes sense for patients to seek out trained genetic counselors and practitioners to help them decide whether to be tested and how to interpret the test results."
INFORMATION:
The lead author of the JAMA Oncology paper is Andrea Desmond of the MGH Cancer Center. Additional co-authors are Michele Gabree, MS, CGC, Nora Horick, MS, and Kristen Shannon, MS, CGC, MGH Cancer Center; Allison Kurian, MD, MSc, Meredith Mills, and James Ford, MD, Stanford University School of Medicine; Nadine Tung, MD, Beth Israel Deaconess Medical Center; and Michael Anderson, PhD, Yuya Kobayashi, PhD, Shan Yang, PhD, and Steven Lincoln, Invitae Corporation, which manufactures one of the multigene panels used in the study. The study was supported by grants from the MGH Friends Fighting Breast Cancer, the Tracey Davis Memorial Fund and the Breast Cancer Research Foundation.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $760 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine. In July 2015, MGH returned into the number one spot on the 2015-16 U.S. News & World Report list of "America's Best Hospitals."
A University of Manchester study which followed up 38,415 people admitted to hospital with self-harm has, for the first time, investigated the association between the treatment patients receive in hospital and their subsequent risk of death.
Published in the Lancet Psychiatry, the study looked at adults who had self-harmed and attended five hospital emergency departments in Manchester, Oxford and Derby between 2000 and 2010. The researchers found that within 12 months, 261 had died by suicide and a further 832 had died from other causes.
The study also examined the ...
Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant, and three times more likely to die of the dangerous skin cancer, suggests new research led by a Johns Hopkins Bloomberg School of Public Health student.
The findings, reported Aug. 13 in the Journal of Investigative Dermatology, suggest that the immunosuppressive medications that transplant recipients receive to keep them from rejecting their new organs -- especially the high doses administered at the time of transplant -- may make them more susceptible to later ...
A study on granting local sales people pricing discretion shows that profits improve by up to 11% when local sales forces are empowered to negotiate with customers. However a centralized system that uses optimization techniques and limits local sales discretion improves profits still further, by an additional 20%. The research appears in the current issue of Management Science, a publication of the Institute for Operations Research and the Management Sciences (INFORMS), the leading professional association in analytics and operations research.
"This hybrid approach balances ...
Summary: Children born with the major congenital heart defect hypoplastic left heart syndrome (HLHS) often must undergo a series of corrective surgeries beginning at birth. While most have the standard three-stage Norwood procedure, a hybrid strategy has been introduced to offset some disadvantages associated with the Norwood surgeries. In a report in The Journal of Thoracic and Cardiovascular Surgery, investigators compare whether outcomes can be improved if an arterial shunt is used as a source of pulmonary blood flow rather than the more conventional venous shunt as ...
For smokers, the number of cigarettes smoked per day and current body mass index are predictive of changes in weight after quitting smoking, according to researchers at Penn State College of Medicine.
Quitting smoking may lead to some weight gain but how much weight gain depends on the individual. Previous research shows that for some it can be just a few pounds, but for others it can be more than 25 pounds. Unfortunately, factors that can help predict the amount of weight a smoker may gain are not well understood.
"Many smokers are concerned about gaining weight after ...
PHOENIX -- A multicenter study involving Mayo Clinic researchers has found that the National Cancer Institute's Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), was accurate, reliable and responsive, compared to other, established patient-reported and clinical measures. The study is published today in the journal JAMA Oncology.
"In most cancer clinical trials, information on side effects is collected by providers who have limited time with their patients and current patient questionnaires are limited in scope and depth," ...
Early humans were the dominant cause of the extinction of a variety of species of giant beasts, new research has revealed.
Scientists at the universities of Exeter and Cambridge claim their research settles a prolonged debate over whether mankind or climate change was the dominant cause of the demise of massive creatures in the time of the sabretooth tiger, the woolly mammoth, the woolly rhino and the giant armadillo.
Known collectively as megafauna, most of the largest mammals ever to roam the earth were wiped out over the last 80,000 years, and were all extinct by ...
The discovery of antidepressant drugs in the 1950s led to the first biochemical hypothesis of depression, known as the monoamine hypothesis. This hypothesis proposes that an imbalance of certain brain chemicals is the key cause of depression. Research has investigated whether and to what degree the "reward and pleasure" chemical dopamine and, more recently, the "happiness" chemical serotonin, could be the neurotransmitters involved in the malady. However, the monoamine hypothesis does not seem to fully explain the complexity of human depression. Now a new study offers one ...
August 13, 2015--A visit to the dentist has the potential to be more than a checkup of our teeth as patients are increasingly screened for medical conditions like heart disease and diabetes. A new study by researchers at Columbia University's Mailman School of Public Health focuses on dental screenings for drug misuse, finding 77 percent of dentists ask patients about illicit drug use, and 54 percent of dentists believe that such screenings should be their responsibility. Results of the study are online in the journal Addiction.
"There are a sizeable number of people ...
TORONTO, (Aug. 13, 2015) - Low birth weight and preterm birth appear to increase the risk of schizophrenia among individuals with a genetic condition called the 22q11.2 deletion syndrome, a new study from the Centre for Addiction and Mental Health (CAMH) shows.
The research, published in Genetics in Medicine, is "...part of ongoing efforts among schizophrenia researchers to predict and prevent illness at the earliest stages possible," says senior author Dr. Anne Bassett, Clinician-Scientist in CAMH's Campbell Family Mental Health Research Institute and Canada Research ...
